HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trump Meets With Two FDA Commissioner Candidates; Third Still In Play

This article was originally published in The Rose Sheet

Executive Summary

O'Neill and Srinivasan head to Trump Tower, but Gottlieb has not been eliminated.

You may also be interested in...



US FDA’s Bipartisan Support May Offer Shelter From Political Winds, Former Chief Says

In the wake of 21st Century Cures legislation, next commissioner will have strong support across party lines to undertake smarter regulation aimed at improving the efficiency of the drug development process, former FDA head McClellan says.

US FDA Might Be Temporarily Headed By Ostroff As Califf Sets His Departure

Former acting commissioner in line for the temporary position again under FDA policy, unless incoming Trump administration designates someone else.

Woodcock Tries To Calm US FDA Staff Fears About Trump

CDER Director's' video advises focusing on the work and "keeping our heads down."

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS109025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel